PCRX

$21.94

Market ClosedAs of Mar 17, 8:00 PM UTC

Pacira BioSciences, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$21.94
Potential Downside
86.7%
Whystock Fair Value$2.91
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupiva...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$943.89M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
137.13
Beta
Defensive asset. Lower volatility than the S&P 500.
0.23
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
0.96%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.01

Recent News

MT Newswires
Mar 11, 2026

Sector Update: Health Care Stocks Lower Late Afternoon

Health care stocks were slipping late Wednesday afternoon, with the NYSE Health Care Index down 0.5%

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Feb 28, 2026

Assessing Pacira BioSciences (PCRX) Valuation After Recent Share Price Weakness

Recent share performance and business snapshot Pacira BioSciences (PCRX) has been under pressure recently, with the stock showing a 3% decline over the past day and a 5.6% decline over the past week, while still positive over the past month. At a last close of US$21.91, Pacira carries a value score of 2 and reports annual revenue of US$726.41m and net income of US$7.03m. The company has a specialized focus on non opiod pain management products. See our latest analysis for Pacira...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 27, 2026

Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down

PCRX misses Q4 earnings and revenue estimates as expenses surge and shares slide, despite Exparel growth and a new 2026 outlook.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Moby
Feb 27, 2026

Pacira BioSciences, Inc. Q4 2025 Earnings Call Summary

Moby summary of Pacira BioSciences, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
MarketBeat
Feb 27, 2026

Pacira BioSciences Q4 Earnings Call Highlights

Pacira BioSciences (NASDAQ:PCRX) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight what CEO Frank Lee described as a “transformative year,” pointing to renewed EXPAREL volume momentum, strengthened intellectual property protection, expanded reimbursement cove

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.